From the Department of Medicine, Division of Respirology, University of Ottawa, Ottawa, Ontario, Canada.
Department of Medicine, Division of Respirology, University of Alberta, Edmonton, Alberta, Canada.
Respiration. 2018;96(6):552-559. doi: 10.1159/000491097. Epub 2018 Sep 11.
Indwelling pleural catheters (IPC) are commonly used in the management of malignant pleural effusions (MPE). The effect of systemic chemotherapy on IPC removal has not been reported previously.
The purpose of this study is to identify the effect of chemotherapy on the removal of IPCs in breast cancer patients with MPEs.
In this retrospective cohort study at an academic tertiary-care center, patients with breast cancer and MPE who received an IPC between 2006 and 2016 were identified from a prospectively collected database. Patient chemotherapy data were obtained, as well estrogen receptor (ER) and human epidermal growth factor receptor-2 status at the time of diagnosis. Patients receiving chemotherapy while their IPC was in situ were compared to those who did not. The primary outcome was time to IPC removal. All patients were followed until IPC removal or death.
A total of 207 patients and 216 IPCs were included in the analysis. There was no difference in time to IPC removal between the chemotherapy and no-chemotherapy groups (HR 0.73, 95% CI 0.50-1.07, p = 0.10) or rate of IPC removal (OR 1.16, 95% CI 0.68-1.98, p = 0.59). The risk of IPC infection was not different between patients who received chemotherapy and those who did not (RR 0.57, 95% CI 0.06-5.39, p = 0.48).
Treatment with chemotherapy with an IPC in situ was not associated with a reduced time to IPC removal in our breast cancer population. IPC insertion in patients receiving chemotherapy is safe and not associated with an increased risk of infection.
留置性胸腔导管(IPC)常用于管理恶性胸腔积液(MPE)。先前尚未报道全身性化疗对 IPC 移除的影响。
本研究旨在确定化疗对伴有 MPE 的乳腺癌患者 IPC 移除的影响。
在一家学术性三级护理中心进行的这项回顾性队列研究中,从一个前瞻性收集的数据库中确定了 2006 年至 2016 年间接受 IPC 的患有乳腺癌和 MPE 的患者。获取了患者的化疗数据,以及诊断时的雌激素受体(ER)和人表皮生长因子受体-2 状态。比较了在 IPC 在位时接受化疗的患者和未接受化疗的患者。主要结局是 IPC 移除的时间。所有患者均随访至 IPC 移除或死亡。
共有 207 例患者和 216 个 IPC 纳入分析。化疗组和非化疗组之间的 IPC 移除时间无差异(HR 0.73,95%CI 0.50-1.07,p=0.10)或 IPC 移除率(OR 1.16,95%CI 0.68-1.98,p=0.59)。接受化疗和未接受化疗的患者之间 IPC 感染的风险没有差异(RR 0.57,95%CI 0.06-5.39,p=0.48)。
在我们的乳腺癌人群中,IPC 在位时接受化疗与 IPC 移除时间的缩短无关。在接受化疗的患者中插入 IPC 是安全的,并且不会增加感染的风险。